Arch Therapeutics Inc (ARTH)

[Regis999]

Anytime a hole in the body occurs one needs to worry about bleeding, leaking and contamination to mitigate infection.

Arch’s AC5 to address these needs. Arch intends to transform the landscape of interventional healthcare with products to seal and protect leaking and bleeding tissue.


The Company’s product, AC5, a liquid peptide, should result in faster, safer, simpler surgery with substantial savings in time of surgery (some have estimated potentially up to 60%).



"The operation would be much shorter. We go from a bypass surgery that may take six hours to a bypass surgery that may take 45 minutes. Or a neurosurgery that may take three or four hours, to one that takes 20 minutes. So, it completely changes how you think about surgery.” “And it’s not just hemostasis. If you look at surgery for instance, let’s say we create a barrier that will stop the movement of bacteria. It will stop the growth of bacteria, and if you could stop the possible infection in that operating room, the recovery time would be faster.”


http://www.pnas.org/site/misc/ellis-behnkePodcastTranscript.pdf


Presentation by Founder of AC5 Dr. Rutledge Ellis-Behnke PHD using AC5 on animals



AC5 Surgical HemostatTM is an Effective Hemostatic Agent in Anticoagulated Animals



You Tube Video

Dr. Rutledge Ellis-Behnke, PhD Linkedin BIO https://www.linkedin.com/in/nanomedicine





Thought: In the future AC5 will be combined with other agents to promote such things as healing, infection, etc. etc. etc. This will not be Arch but others.